Springfield Pharma Profile
Key Indicators
- Authorised Capital ₹ 30.10 Cr
as on 30-07-2024
- Paid Up Capital ₹ 28.00 Cr
as on 30-07-2024
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -3947.37%
(FY 2023)
- Ebitda -3947.37%
(FY 2023)
- Net Worth -1266.70%
(FY 2023)
- Total Assets 225652.05%
(FY 2023)
About Springfield Pharma
The Corporate was formerly known as Springfield Nutrition Private Limited. The Company is engaged in the Real Estate And Construction Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 30.10 Cr and a paid-up capital of Rs 28.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Springfield Pharma Private Limited India is Koushal Rathi as COMPANY SECRETARY. Ravender Rao, Suguna Raman, and Phalgun Gorukanti serve as directors at the Company.
- CIN/LLPIN
U74110TG2014PTC095339
- Company No.
095339
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Aug 2014
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Springfield Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Koushal Rathi | Company Secretary | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravender Rao  | Director | 20-Aug-2014 | Current |
| Suguna Raman | Director | 20-Aug-2014 | Current |
| Phalgun Gorukanti | Director | 30-May-2019 | Current |
Financial Performance of Springfield Pharma.
Springfield Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 3947.37% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1266.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Springfield Pharma?
In 2023, Springfield Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Yashoda Healthcare Services Private LimitedActive 31 years 5 monthsRavender Rao, Phalgun Gorukanti and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Springfield Pharma?
Unlock and access historical data on people associated with Springfield Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Springfield Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Springfield Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
